Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26776003 | 0.89 | CRBN (0.53) | CRBNCYP2C9ADRA1AHRH1MAOA | |
| SCHEMBL31312068 | 0.88 | CRBN (0.55) | CRBNCYP2C9ADRA1AHRH1MAOA | |
| SCHEMBL31409560 | 0.88 | CRBN (0.58) | CRBNCYP2C9ADRA1AHRH1MAOA | |
| SCHEMBL25894316 | 0.87 | CRBN (0.54) | CRBNMAOAMAOBPRKCI | |
| SCHEMBL16850280 | 0.86 | CRBN (0.56) | CRBNMAOAMAOBPRKCIPOLB | |
| SCHEMBL16850281 | 0.86 | CRBN (0.56) | CRBNMAOAMAOBPRKCIPOLB | |
| SCHEMBL30763946 | 0.85 | CRBN (0.53) | CRBNMAOAMAOBPRKCIPARP1 | |
| SCHEMBL787033 | 0.85 | HRH3 (0.54) | CRBNMAOAMAOBPRKCIESR2 | |
| SCHEMBL31312061 | 0.85 | CRBN (0.52) | CRBNCYP2C9ADRA1AHRH1MAOA | |
| SCHEMBL29798717 | 0.85 | HRH3 (0.54) | CRBNMAOAMAOBPRKCIESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025019598-A1 | POSITIVE ALLOSTERIC MODULATOR OF THE METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 2 RECEPTOR, SYNTHESIS AND SOLID FORMS THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-01-23 | — | — | WO | claimed |
| WO-2025019598-A1 | POSITIVE ALLOSTERIC MODULATOR OF THE METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 2 RECEPTOR, SYNTHESIS AND SOLID FORMS THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025006553-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024263563-A1 | METABOTROPIC GLUTAMATE SUBTYPE-2 AND -3 RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-12-26 | — | — | WO | disclosed |
| US-8748632-B2 | Positive allosteric modulators of group II mGluRs | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748632-B2 | Positive allosteric modulators of group II mGluRs | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748632-B2 | Positive allosteric modulators of group II mGluRs | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2011116356-A2 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011116356-A2 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | GRM2, GRM1, GRIN2C | CRBN 2305/4885CYP2C9 3909/4885ADRA1A 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.